Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines, Inc. (PRAX)
:PRAX
RESEARCH TOOLSreports
Holding PRAX?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-2.85Last Year’s EPS
-2.97Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 11, 2021
|% Change Since: -3.01%
|Next Earnings Date:Mar 17, 2021
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Praxis's pipeline, particularly with promising results in their epilepsy programs and a solid financial position. However, there were concerns about delays in clinical trial timelines and challenges in managing placebo effects, which could impact future outcomes.Company Guidance
During the Praxis Precision Medicine Q3 2024 earnings call, the company provided guidance on significant upcoming milestones and key metrics. The company anticipates having four programs in registration by next year, targeting a multibillion-dollar opportunity. For their lead program, ulixacaltamide, the Phase III ESSENTIAL3 study is expected to yield results in Q1 2025, with interim analyses in the coming months. In their epilepsy pipeline, the Phase II EMBOLD trial showed promising results, with relutrigine achieving a 46% reduction in motor seizures among 15 patients, leading to the initiation of a second registrational cohort. Additionally, their Empower observational study attracted over 1,000 patients in a short time. Financially, Praxis reported Q3 operating expenses of $57.1 million, with $41.9 million allocated to R&D, and ended the quarter with $411.2 million in cash, ensuring runway into 2027.Positive Top-line Results for Vormatrigine
In a Phase II trial, Vormatrigine demonstrated a 46% reduction in motor seizures compared to placebo, with 33% of patients achieving seizure-free status.
Strong Financial Position
Praxis ended Q3 with $411.2 million in cash, cash equivalents, and marketable securities, providing a funding runway into 2027.
Pipeline Progress
Praxis is advancing four programs in registration, aiming for a substantial multibillion-dollar market opportunity.
Interest in Epilepsy Program
The Empower study attracted over 1,000 patients shortly after its launch, indicating strong interest in the comprehensive epilepsy program.
---
PRAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PRAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $72.73 | $71.87 | -1.18% |
| Aug 13, 2024 | $51.82 | $52.24 | +0.81% |
| Mar 05, 2024 | $54.71 | $53.68 | -1.88% |
| Nov 07, 2023 | $14.79 | $15.75 | +6.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Praxis Precision Medicines, Inc. (PRAX) report earnings?
Praxis Precision Medicines, Inc. (PRAX) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Praxis Precision Medicines, Inc. (PRAX) earnings time?
Praxis Precision Medicines, Inc. (PRAX) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRAX EPS forecast?
PRAX EPS forecast for the fiscal quarter 2024 (Q4) is -2.85.
---